TOP > 外国特許検索 > PEPTIDE INHIBITING DIFFERENTIATION OF HEMATOPOIETIC STEM CELLS OR HEMATOPOIETIC PRECURSOR CELLS AND USE OF SAME

PEPTIDE INHIBITING DIFFERENTIATION OF HEMATOPOIETIC STEM CELLS OR HEMATOPOIETIC PRECURSOR CELLS AND USE OF SAME

外国特許コード F120006574
整理番号 QP080065-PC
掲載日 2012年5月14日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2010JP067011
国際公開番号 WO 2011040500
国際出願日 平成22年9月29日(2010.9.29)
国際公開日 平成23年4月7日(2011.4.7)
優先権データ
  • 特願2009-224088 (2009.9.29) JP
発明の名称 (英語) PEPTIDE INHIBITING DIFFERENTIATION OF HEMATOPOIETIC STEM CELLS OR HEMATOPOIETIC PRECURSOR CELLS AND USE OF SAME
発明の概要(英語) Disclosed is a novel peptide effectively usable in constructing or proliferating in vitro tissue-specific stem cells or tissue-specific precursor cells. The peptide, which is a peptide having an amino acid sequence comprising the amino acid residues represented by SEQ ID NO:1 or an analog of the same, is characterized by having at least one of the following effects: (1) an effect of inhibiting the differentiation of hematopoietic stem cells or hematopoietic precursor cells into myelocytic cells; (2) an effect of promoting the amplification of mesenchymal stem cells; and (3) an effect of inducing hematopoietic stem cells from pluripotent cells.
従来技術、競合技術の概要(英語) BACKGROUND ART
Hematopoietic stem cells produced in vitro from pluripotent stem cells, also, taken out of the hematopoietic stem cells ex vivo cultured, tumor without causing hematopoietic stem cells as long as the amplifying only, solve many of the problems of transplant-related, adaptation of the hematopoietic stem cell transplantation therapy is not simply by increasing, other organ-specific stem cell transplantation therapy and development, the analyte can be a new regenerative medicine. Have been developed up to now the fabrication method of the hematopoietic stem cells in and amplification procedures, the following drawbacks have been noted.
1. HoxB4 Gene introduced into a pluripotent stem cell, hematopoietic stem cells able to be manufactured of, induction of acute leukemia. 2.HoxB4 gene is introduced into the hematopoietic stem cells, hematopoietic stem cells of the amplifies, induction of acute leukemia. 3. Cytokines induced by the addition of the differentiation of mature blood cells, hematopoietic stem cells in an undifferentiated property difficult to maintain. 4. The addition of the demethylating agent is the amplification efficiency of hematopoietic stem cells is improved, so that the safety affect HDAC verification is needed.
All cell lineage into pluripotent stem cell differentiation is possible in theory, the orientation of their differentiation in vitro is a technique which determines the dependancy and, as applicable in clinical hematopoietic stem cells from pluripotent stem cells may develop a technology for manufacturing is in progress. Those cells with the pluripotency, differentiates into a certain direction to another system is the ability to differentiate and lose holding properties, other than suppressing the differentiation of hematopoietic stem cells, of hematopoietic stem cells from pluripotent stem cells produced can be expected. Hematopoietic stem cells are multipotent at a glance that the ability to self-replicate and the ability to and enable a contradictory, such as cytokines stimulated by the differentiation to mature blood cells are produced. That is amplify hematopoietic stem cells, while at the same time the accelerator pedal to self-replicate, differentiate into various cell lineages is necessary to brake. While avoiding the above problems and new hematopoietic stem cells for the development and amplification procedures for the preparation of the is, hematopoietic stem cells other than suppressing the differentiation factor, only self-replication of hematopoietic stem cells promoting factor, or hematopoietic stem cell differentiation factor to brake the search and development becomes important. Amplification of hematopoietic stem cells in vivo in the liver and is mainly embryonic stage location, this new factor search and development of hematopoietic stem cells in the liver revealed amplification mechanism, the results obtained in vitro in the reproduced take a short cut is straightforward.
Patent Document 1 is, as an active ingredient placenta constituent cell of the crushed hematopoietic stem cell growth agent is disclosed, such biological derived materials are the infection and, with the problem of difficulty in the preparation of the material.
Patent Document 2 is, membrane protein Thsd1/Tmtsp from hematopoietic stem cells maintain and discloses promoting factor, such membrane proteins, to prepare an active form in the difficult.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION KYUSHU UNIVERSITY
  • 発明者(英語)
  • SUGIYAMA, Daisuke
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
上記の特許・技術に関心のある方は、下記問合せ先にご相談下さい。

PAGE TOP

close
close
close
close
close
close